<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255696</url>
  </required_header>
  <id_info>
    <org_study_id>ALV003-1021</org_study_id>
    <secondary_id>2010-023127-23</secondary_id>
    <nct_id>NCT01255696</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease</brief_title>
  <official_title>A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvine Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvine Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Intestinal mucosal morphology</measure>
    <time_frame>6 weeks</time_frame>
    <description>Intestinal mucosal morphology - change from baseline to week 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Tolerability of ALV003</measure>
    <time_frame>6 weeks</time_frame>
    <description>Safety will be evaluated by collection of adverse events, blood chemistry and blood cell counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in intestinal intraepithelial lymphocyte numbers/phenotype</measure>
    <time_frame>6 weeks</time_frame>
    <description>Intestinal intraepithelial lymphocyte numbers/phenotype - change from baseline to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in serological markers of celiac disease</measure>
    <time_frame>6 weeks</time_frame>
    <description>Serological markers of celiac disease - change from baseline to week 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>ALV003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipients for ALV003 absent the experimental compounds</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALV003</intervention_name>
    <arm_group_label>ALV003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALV003 placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of biopsy-proven celiac disease

          -  Adherence to a gluten-free diet

          -  TG2 antibody negative

          -  Signed informed consent

        Exclusion Criteria:

          -  Active dermatitis herpetiformis

          -  History of IgE-mediated reactions to gluten

          -  Use of specific medications 6 months prior to entry

          -  History of alcohol abuse or illicit drug use

          -  Current untreated or GI disease

          -  Positive pregnancy test

          -  Received any experimental drug within 14 days of randomization

          -  Uncontrolled chronic disease or condition

          -  Uncontrolled complications of celiac disease

          -  Any medical condition which could adversely affect study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marja-Leena Lähdeaho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FINN-MEDI Research Oy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markku Mäki, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tampere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Terveystalo Kuopio</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Diakonissalaitos (ODL)</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FINN-MEDI Research Oy - Clinical Trials Center</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <disposition_first_submitted>July 13, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 30, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 6, 2012</disposition_first_posted>
  <last_update_submitted>July 30, 2012</last_update_submitted>
  <last_update_submitted_qc>July 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Celiac Disease</keyword>
  <keyword>Coeliac Disease</keyword>
  <keyword>Celiac Sprue</keyword>
  <keyword>Keliakia Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

